Aadi Bioscience to Report Fourth Quarter and Full-Year 2022 Results and Corporate Update

Rhea-AI Summary

Aadi Bioscience, a biopharmaceutical firm, will host a conference call on March 28, 2023, at 8:30 AM EDT to discuss its fourth quarter and full-year 2022 financial results and corporate updates. The call will be accessible via live webcast on their website. Aadi specializes in precision therapies for genetically-defined cancers, notably receiving FDA approval for FYARRO® to treat advanced malignant perivascular epithelioid cell tumors. Additionally, they are initiating the PRECISION 1 trial targeting solid tumors with specific genetic alterations.

Company to Host Conference Call and Webcast on March 28, 2023

LOS ANGELES, March 15, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that it will host a conference call and live webcast on Tuesday, March 28, 2023 at 8:30 am EDT (5:30 am PDT) to report fourth quarter and full-year 2022 financial results and provide recent corporate updates.

Conference Call Information 

Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com. To participate via telephone, please register in advance here: Conference Registration (vevent.com). Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the website for at least 30 days.

About Aadi Bioscience, Inc.

Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for genetically defined cancers to bring transformational therapies to cancer patients with mTOR pathway driver alterations. Aadi received FDA approval and has commercialized FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Aadi has also initiated PRECISION 1, a Phase 2 tumor-agnostic registration-intended trial in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on the Company's development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.

Contact:
Marcy Graham
IR@aadibio.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-report-fourth-quarter-and-full-year-2022-results-and-corporate-update-301772563.html

SOURCE Aadi Bioscience

FAQ

When will Aadi Bioscience report its fourth quarter and full-year 2022 financial results?

Aadi Bioscience will report its financial results on March 28, 2023.

How can I access the Aadi Bioscience conference call on March 28, 2023?

You can access the conference call via live webcast on the Aadi Bioscience website.

What is Aadi Bioscience's focus in biopharmaceuticals?

Aadi Bioscience focuses on developing precision therapies for genetically-defined cancers.

What FDA-approved treatment does Aadi Bioscience offer?

Aadi Bioscience offers FYARRO®, approved for treating advanced malignant perivascular epithelioid cell tumors.

What is the PRECISION 1 trial initiated by Aadi Bioscience?

The PRECISION 1 trial is a Phase 2 study targeting solid tumors with specific mTOR pathway gene alterations.